The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in
hepatitis C positive patients undergoing liver transplantation. The hypothesis is that
patients who receive ribavirin immediately before transplant and intravenous interferon alfa
2b during the anhepatic phase(while the liver is removed)will have sustained virologic
response post liver transplant.